Preventing medication errors with antineoplastic agents, part 2

Hospital Pharmacy

Volumn 35, Issue 7, 2000, Pages 732-747

  Beckwith, M Christina ^a   Tyler, Linda S ^a  

^a UNIVERSITY OF UTAH HOSPITAL   (United States)

Author keywords

Antineoplastic agents; Chemotherapy; Continuous quality improvement; Iatrogenic disease; Medication errors; Quality assurance

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; COMPETENCE; DRUG INDUCED DISEASE; DRUG STORAGE; DRUG SURVEILLANCE PROGRAM; HEALTH CARE QUALITY; HOSPITAL PHARMACY; HUMAN; IATROGENIC DISEASE; MEDICAL LITERATURE; PHARMACIST; PRESCRIPTION; SHORT SURVEY;

EID: 0033942880     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870003500703     Document Type: Short Survey

References (51)

1. Errors in health care: A leading cause of death and injury. In: Kohn LT, Corrigan JM, Donaldson M, eds. To Err is Human: Building a Safer Health System. Washington, DC: Committee on Quality of Health Care in America, Institute of Medicine, National Academy of Sciences; 2000, 26-48.
2. Cohen MR, Institute for Safe Medication Practices. Current Issues in Medication Safety: HealthInsight's Meeting on Adverse Drug Events: Reducing Medication Errors in Utah. Salt Lake City, UT: Health Insight; February 18, 1998.
3. Cohen MR, Anderson RW, Attilio RM, et al. Preventing medication errors in cancer chemotherapy. Am J Health Syst Pharm. 1996;53:737-46.
4. Seven steps for preventing lethal chemotherapy overdoses. Nursing. 1997; 27:49.
5. Top-priority actions for preventing adverse drug events in hospitals. Recommendations of an expert panel. Am J Health Syst Pharm. 1996; 53:747-51.
6. Attilio RM. Caring enough to understand: The road to oncology medication error prevention. Hosp Pharm. 1996; 31:17-26.
7. Pharmacy and Therapeutics Committee, University of Utah Hospitals and Clinics. Medication Ordering of Antineoplastic Agents at University Hospitals and Clinics: Policy and Procedure Manual. Salt Lake City, UT; 1998.
8. Schwarz LR. Delivering cytotoxic chemotherapy safely in a community hospital. Hosp Pharm. 1996;31:1108-18.
9. Hutcherson DA, Gammon DC. Preventing errors with antineoplastic agents: A pharmacist's approach. Hosp Pharm. 1997; 32:190-202,209.
10. Bartel S, Smetzer J, Institute for Safe Medication Practices. Chemotherapy-Focused System Analysis of the Medication Use Process at University of Utah Hospital. Huntingdon Valley, PA: Institute for Safe Medication Practices; 1999.
11. Trinkle R, Wu JK. Sources of medication errors involving pediatric chemotherapy patients. Hosp Pharm. 1997;32:853-9.
12. Ukens C. Deadly dispensing: An exclusive survey of Rx errors by pharmacists. Drug Topics. 1997;March 3:100,102,104, 107-8, 111-12.
13. Trinkle R, Wu JK. Errors involving pediatric patients receiving chemotherapy: A literature review. Med Pediatr Oncol. 1996; 26:344-51.
14. Cousins DH, Upton DR, Cohen MR. Reducing the risks of chemotherapy errors. Hosp Pharmacist. 1995;2:117-20.
15. Berard CM, Mahoney CD, Welch DW, Rodrigues TD. Computer software for pharmacy oncology services. Am J Health Syst Pharm. 1996; 53:752-6.
16. Aiming at administering: Practice recommendations to prevent errors. USP Quality Review. 2000;71 (January):1-2.
17. Cohen MR. ISMP medication error report analysis. Hosp Pharm. 1999; 34:528-32.
18. Schulmeister L. Chemotherapy medication errors: Descriptions, severity, and contributing factors. Oncol Nurs Forum. 1999; 26:1033-42.
19. Anderson RA, Wolff JE, Egeler RM, et al. Infallible measures needed to prevent errors in the administration of chemotherapeutic agents. Med Pediatr Oncol. 1999; 32:401-2.
20. Whitmore CK, Wardian SM. Chemotherapy administration precheck verification. Hosp Pharm. 1985; 20:751-4.
21. Fernandez CV, Esau R, Hamilton D, et al. Intrathecal vincristine: An analysis of reasons for recurrent fatal chemotherapeutic error with recommendations for prevention. J Pediatr Hematol Oncol. 1998; 20:587-90.
22. Ignoffo RJ. Preventing chemotherapy errors. Am J Health Syst Pharm. 1996; 53:733.
23. Jardine LF, Ingram LC, Bleyer WA. Intrathecal leucovorin after intrathecal methotrexate overdose. J Pediatr Hematol Oncol. 1996; 18:302-4.
24. Sellers JA. Too many medication errors, not enough pharmacists. Am J Health Syst Pharm. 2000;57:337.
25. Buchanan TL, Barker KN, Gibson JT, et al. Illumination and errors in dispensing. Am J Hosp Pharm. 1991;48:2137-45.
26. Knox RA. State cites Dana Farber failures; quality assurance program faulted. Boston Globe. May 31, 1995:21.
27. Gilmore CE, Suresky P. Development and implementation of a chemotherapy error-prevention policy. Hosp Pharm. 1998; 33:1214-9.
28. Lunik MC, Peters BG,Wilson AL. Quality-improvement processes in an oncology pharmacy service. Am J Health Syst Pharm. 1996; 53:757-9.
29. Leape LL. Error in medicine. JAMA. 1994;272:1851-7.
30. Fitzgerald WL, Wilson DB. Medication errors: Lessons in law. Drug Topics. 1998; January 19:84-93.
31. Rich DS. Meeting Joint Commission requirements for competence assessment. Am J Health Syst Pharm. 1996;53:726-9.
32. Leape LL. Faulty systems, not faulty people. Boston Globe. January 12, 1999:A15.
33. Knox RA. 18 nurses face state action in chemotherapy overdoses. Boston Globe. January 5, 1999:A1.
34. Knox RA. Licensing Board reprimands 3 Dana-Farber pharmacists. Boston Globe. September 26, 1996:B2.
35. Tracy EM. Evolving practice and a culture of safety. Driving out fear breeds pervasive change. QRC Advis. 1999; 15:10-12.
36. Marquis J, Rubin AJ. National perspective, health: Hospitals, doctors fear fallout of call for error reporting. Los Angeles Times. February 23, 2000:A5.
37. News Services. Clinton calls on hospitals to reduce errors that claim thousands of lives; medical groups oppose mandatory reporting. St. Louis Post-Dispatch, February 23, 2000:A1.
38. Wilcox E. ASHP supports White House medical-error reduction plan. Available online at www.ashp.org/public/news/ releases/nr2000-10.html. Bethesda, MD: American Society of Health-System Pharmacists; accessed on April 4, 2000.
39. Wilcox E. ASHP proposes critical steps in national solution to medical error. Available online at www.ashp.org/public/news/ releases/nr2000-7.html. Bethesda, MD: American Society of Health-System Pharmacists; accessed on April 4, 2000.
40. Wakefield DS, Wakefield BJ, Uden-Holman T, et al. Understanding why medication administration errors may not be reported. Am J Med Qual. 1999; 14:81-8.
41. Meisel S, Sershon L, White D. Reducing adverse drug events and medication errors using rapid cycle improvement. Qual Manag Health Care. 1998; 6:15-28.
42. Hume M. Changing hospital culture and systems reduces drug errors and adverse events. Qual Lett Healthc Lead. 1999; 11:2-9.
43. Hume M. Changing hospital culture, systems reduces drug errors. Exec Solut Healthcare Manage. 1999;2:1,4-9.
44. Trissel LA. Medication errors: Integrating individual and system accountability. Am J Health Syst Pharm. 1999;56:1263-4.
45. Golz B, Fitchett L. Nurses' perspective on a serious adverse drug event. Am J Health Syst Pharm. 1999; 56:904-7.
46. Sanks RJ. A pharmacy manager's perspective on a serious adverse drug event. Am J Health Syst Pharm. 1999; 56:907-9.
47. Sentinel events. Available online at www.jcaho.org/sentinel/sentevnt_frm.htm 1. Oakbrook Terrace, IL: Joint Commission on Accreditation of Healthcare Organizations; accessed on April 7, 2000.
48. Discussion paper on adverse event and error reporting in healthcare. January 24, 2000. Available online at www.ismp.org. Huntingdon Valley, PA: Institute for Safe Medication Practices; accessed on April 7, 2000.
49. Roush W. Dana-Farber death sends a warning to research hospitals. Science. 1995;269:295-6.
50. Proulx S, Wilfinger R, Cohen MR. Medication error prevention: Profiling one of pharmacy's foremost advocacy efforts for advice on error prevention. Pharm Pract Manag Q. 1997;17:1-9.
51. Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA. 1995; 274:35-43.